Moving erlotinib from formulary tier 3 to tier 2 resulted in lower copayments and higher treatment persistence among lung cancer patients.
Feng Cao, PhD
Advertisement
Articles by Feng Cao, PhD
Advertisement
Latest Updated Articles
- Lung Cancer: Copayments and Behavior Following Erlotinib Formulary Tier Change
Published: November 13th 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Mind the Gap: Pharmacy’s Future as AI Evolves in Health Care
2
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
3
Pharmacists Are Essential Partners in Modern Disease Management and Immunization Efforts
4
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
5
